Last reviewed · How we verify
Sodium Chloride, (24)NaCl 0,9%
Sodium Chloride, (24)NaCl 0,9% is a Electrolyte replacement solution Small molecule drug developed by University of Oulu. It is currently FDA-approved for Fluid and electrolyte replacement in dehydration, Vehicle for intravenous drug administration, Wound irrigation and topical cleansing. Also known as: saline.
Sodium chloride 0.9% solution restores and maintains electrolyte balance and fluid volume in the body.
Sodium chloride 0.9% solution restores and maintains electrolyte balance and fluid volume in the body. Used for Fluid and electrolyte replacement in dehydration, Vehicle for intravenous drug administration, Wound irrigation and topical cleansing.
At a glance
| Generic name | Sodium Chloride, (24)NaCl 0,9% |
|---|---|
| Also known as | saline |
| Sponsor | University of Oulu |
| Drug class | Electrolyte replacement solution |
| Modality | Small molecule |
| Therapeutic area | General/Supportive Care |
| Phase | FDA-approved |
Mechanism of action
This isotonic saline solution contains sodium and chloride ions in physiological concentrations (0.9% w/v), matching the osmolarity of blood plasma. It is used intravenously or topically to replace lost fluids, maintain hydration, and preserve electrolyte homeostasis without causing cellular osmotic stress. The solution serves as a fundamental vehicle for drug delivery and fluid resuscitation in clinical settings.
Approved indications
- Fluid and electrolyte replacement in dehydration
- Vehicle for intravenous drug administration
- Wound irrigation and topical cleansing
- Maintenance of fluid balance perioperatively
Common side effects
- Hypernatremia (with excessive or prolonged use)
- Fluid overload/pulmonary edema (in susceptible patients)
- Hyperchloremic acidosis (with large volume infusion)
- Local irritation at injection site
Key clinical trials
- Comprehensive Evaluation in Patients With Meniere's Disease
- Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age (PHASE2)
- Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sodium Chloride, (24)NaCl 0,9% CI brief — competitive landscape report
- Sodium Chloride, (24)NaCl 0,9% updates RSS · CI watch RSS
- University of Oulu portfolio CI
Frequently asked questions about Sodium Chloride, (24)NaCl 0,9%
What is Sodium Chloride, (24)NaCl 0,9%?
How does Sodium Chloride, (24)NaCl 0,9% work?
What is Sodium Chloride, (24)NaCl 0,9% used for?
Who makes Sodium Chloride, (24)NaCl 0,9%?
Is Sodium Chloride, (24)NaCl 0,9% also known as anything else?
What drug class is Sodium Chloride, (24)NaCl 0,9% in?
What development phase is Sodium Chloride, (24)NaCl 0,9% in?
What are the side effects of Sodium Chloride, (24)NaCl 0,9%?
Related
- Drug class: All Electrolyte replacement solution drugs
- Manufacturer: University of Oulu — full pipeline
- Therapeutic area: All drugs in General/Supportive Care
- Indication: Drugs for Fluid and electrolyte replacement in dehydration
- Indication: Drugs for Vehicle for intravenous drug administration
- Indication: Drugs for Wound irrigation and topical cleansing
- Also known as: saline
- Compare: Sodium Chloride, (24)NaCl 0,9% vs similar drugs
- Pricing: Sodium Chloride, (24)NaCl 0,9% cost, discount & access